Five patients started the IL-6 inhibitor tocilizumab (Actemra). In the group initiating conventional DMARDs, 71% were on steroids alone and most of the rest were on methotrexate with steroids.

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar developed by Biogen (NASDAQ:BIIB) as an intravenous therapy targeting Roche’s ...

The biosimilar of IL-6 inhibitor tocilizumab, called Tyenne (formerly MSB11456), has been approved for the same indications as Roche’s brand, including rheumatoid arthritis, systemic juvenile ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...